X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (74564) 74564
Newsletter (7437) 7437
Book Review (5140) 5140
Publication (3330) 3330
Conference Proceeding (305) 305
Newspaper Article (288) 288
Book Chapter (227) 227
Dissertation (170) 170
Magazine Article (148) 148
Trade Publication Article (24) 24
Transcript (13) 13
Web Resource (12) 12
Reference (11) 11
Book / eBook (4) 4
Journal / eJournal (4) 4
Paper (4) 4
Data Set (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (59554) 59554
dexamethasone (42890) 42890
humans (37639) 37639
male (27381) 27381
animals (27119) 27119
female (24787) 24787
dexamethasone - pharmacology (23930) 23930
adult (13232) 13232
rats (13186) 13186
middle aged (11912) 11912
dexamethasone - therapeutic use (10134) 10134
dexamethasone - administration & dosage (9857) 9857
aged (7942) 7942
mice (7845) 7845
abridged index medicus (7808) 7808
research (7609) 7609
steroids (7195) 7195
cells, cultured (5817) 5817
oncology (5729) 5729
glucocorticoids - pharmacology (5617) 5617
endocrinology & metabolism (5248) 5248
glucocorticoids (5174) 5174
pharmacology & pharmacy (4950) 4950
treatment outcome (4828) 4828
corticosteroids (4580) 4580
biochemistry & molecular biology (4459) 4459
expression (4443) 4443
hematology (4364) 4364
adolescent (4363) 4363
time factors (4326) 4326
care and treatment (4113) 4113
analysis (4101) 4101
multiple myeloma (4069) 4069
hydrocortisone - blood (3992) 3992
dose-response relationship, drug (3877) 3877
central nervous system depressants (3612) 3612
cell line (3466) 3466
pregnancy (3412) 3412
child (3270) 3270
neurosciences (3265) 3265
cell biology (3242) 3242
therapy (3234) 3234
cancer (3209) 3209
antineoplastic combined chemotherapy protocols - therapeutic use (3189) 3189
drugs (3183) 3183
dexamethasone - adverse effects (2954) 2954
immunology (2895) 2895
reports (2885) 2885
chemotherapy (2865) 2865
inflammation (2834) 2834
surgery (2757) 2757
pediatrics (2735) 2735
rats, sprague-dawley (2706) 2706
kinetics (2677) 2677
cells (2672) 2672
apoptosis (2657) 2657
multiple myeloma - drug therapy (2654) 2654
drug therapy, combination (2525) 2525
receptors, glucocorticoid - metabolism (2508) 2508
bortezomib (2505) 2505
glucocorticoids - administration & dosage (2502) 2502
ophthalmology (2459) 2459
rna, messenger - metabolism (2427) 2427
drug therapy (2382) 2382
health aspects (2365) 2365
gene expression (2329) 2329
gene-expression (2316) 2316
glucocorticoids - therapeutic use (2301) 2301
rats, wistar (2223) 2223
medical research (2201) 2201
aged, 80 and over (2193) 2193
rats, inbred strains (2129) 2129
psychiatry (2112) 2112
anti-inflammatory agents - therapeutic use (2109) 2109
retrospective studies (2109) 2109
anti-inflammatory agents - pharmacology (2098) 2098
prospective studies (2090) 2090
medicine & public health (2048) 2048
dexamethasone - metabolism (2018) 2018
children (2015) 2015
medicine, general & internal (1993) 1993
disease models, animal (1952) 1952
child, preschool (1922) 1922
universities and colleges (1910) 1910
physiological aspects (1882) 1882
infant, newborn (1865) 1865
risk factors (1864) 1864
dosage and administration (1860) 1860
in-vitro (1843) 1843
medicine, experimental (1810) 1810
cortisol (1779) 1779
follow-up studies (1775) 1775
clinical neurology (1772) 1772
activation (1771) 1771
medicine, research & experimental (1743) 1743
physiology (1741) 1741
gene expression regulation - drug effects (1732) 1732
proteins (1697) 1697
clinical trials (1690) 1690
prevention (1688) 1688
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (76071) 76071
German (1385) 1385
French (1055) 1055
Japanese (972) 972
Chinese (807) 807
Spanish (645) 645
Russian (601) 601
Italian (304) 304
Portuguese (237) 237
Polish (204) 204
Korean (180) 180
Czech (83) 83
Dutch (68) 68
Turkish (45) 45
Persian (40) 40
Hungarian (38) 38
Danish (24) 24
Swedish (23) 23
Croatian (19) 19
Romanian (18) 18
Norwegian (17) 17
Bulgarian (16) 16
Serbian (16) 16
Ukrainian (15) 15
Finnish (12) 12
Slovak (11) 11
Hebrew (10) 10
Arabic (5) 5
Indonesian (5) 5
Slovenian (4) 4
Bosnian (2) 2
Icelandic (2) 2
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of clinical endocrinology and metabolism, ISSN 0021-972X, 02/2018, Volume 103, Issue 2, pp. 700 - 700
Journal Article
Clinical Ophthalmology, ISSN 1177-5483, 01/2016, Volume 10, p. 1586
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
Pulse therapy and its modifications in pemphigus: A six year study, 12/2003
Background: Dexamethasone-cyclophosphamide pulse (DCP) therapy for the pemphigus group of disorders is being widely used in India after its introduction in... 
Pemphigus, Dexamethasone-cyclophosphamide pulse, Dexamethasone-azathioprine pulse, Dexamethasone-methotrexate pulse
Journal
Environmental Toxicology and Pharmacology, ISSN 1382-6689, 01/2011, Volume 31, Issue 1, p. 258
Tricothecene mycotoxins, such as nivalenol, are toxic to leukocytes. To elucidate the molecular mechanism of nivalenol toxicity, we investigated the... 
Dexamethasone
Journal Article
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | SURVIVAL | PLUS DEXAMETHASONE | COMPLETE REMISSION | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2015, Volume 201, pp. 32 - 40
Journal Article
Cancer, ISSN 0008-543X, 12/2004, Volume 101, Issue 12, pp. 2788 - 2801
BACKGROUND. Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia (ALL). With these regimens,... 
acute lymphocytic leukemia (ALL) | hyperfractionated cyclophosphamide | vincristine | doxorubicin | long‐term follow‐up | and dexamethasone (Hyper‐CVAD) regimen | Acute lymphocytic leukemia (ALL) | Hyperfractionated cyclophosphamide | Long-term follow-up | And dexamethasone (Hyper-CVAD) regimen | Doxorubicin | Vincristine | MAINTENANCE CHEMOTHERAPY | COMPLETE REMISSION | STANDARD-RISK | BONE-MARROW-TRANSPLANTATION | ALLOGENEIC TRANSPLANT | CHILDHOOD | doxorubicin, and dexamethasone (Hyper-CVAD) regimen | THERAPY | ONCOLOGY | longterm follow-up | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHILDRENS CANCER GROUP | GROUP-B | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Risk | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Remission Induction | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Cyclophosphamide | Care and treatment | Dexamethasone | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 08/2015, Volume 93, Issue 5, pp. 411 - 415
PurposeTo evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non-infectious uveitic macular oedema and vitritis.... 
dexamethasone–cyclodextrin nanoparticle eye drops | non‐infectious uveitis | 1.5% dexamethasone nanoparticle eye drops | vitritis | intermediate uveitis | uveitic macular oedema | non-infectious uveitis | dexamethasone-cyclodextrin nanoparticle eye drops | MULTICENTER | CLINICAL-TRIAL | EFFICACY | DRUG-DELIVERY | DIFLUPREDNATE | 5% dexamethasone nanoparticle eye drops | TRIAMCINOLONE ACETONIDE | SUSPENSION | FLUOCINOLONE ACETONIDE IMPLANT | POSTERIOR UVEITIS | OPHTHALMOLOGY | COMPLICATIONS | Dexamethasone - chemistry | Glucocorticoids - administration & dosage | Prospective Studies | Follow-Up Studies | Nanoparticles - chemistry | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Dexamethasone - analogs & derivatives | Visual Acuity - drug effects | Ophthalmic Solutions | Female | Glucocorticoids - adverse effects | Dexamethasone - administration & dosage | Uveitis - drug therapy | Pilot Projects | beta-Cyclodextrins - adverse effects | beta-Cyclodextrins - administration & dosage | beta-Cyclodextrins - chemistry | Eye Diseases - drug therapy | Macular Edema - drug therapy | Glucocorticoids - chemistry | Aged | Administration, Topical | Retina - pathology | Vitreous Body - drug effects | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Oftalmologi | Ophthalmology | termediate uveitis | Klinisk medicin
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 12/2018, Volume 96, Issue S261, pp. 106 - 106
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3622 - 3630
The salvage infusional chemotherapy regimens, including DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin), VTD‐PACE (bortezomib, thalidomide,... 
multiple myeloma | CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) | VTD‐PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) | salvage | chemotherapy | DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) | VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) | DEXAMETHASONE | MULTICENTER | BORTEZOMIB | TRANSPLANTATION | MAINTENANCE | THERAPY | ONCOLOGY | PHASE-1 | DCEP | LENALIDOMIDE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Dexamethasone - adverse effects | Male | Neoplasm Recurrence, Local - mortality | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Multiple Myeloma - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Infusions, Parenteral | Etoposide - administration & dosage | Treatment Outcome | Thalidomide - administration & dosage | Bortezomib - administration & dosage | Bortezomib - adverse effects | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Salvage Therapy - methods | Care and treatment | Chemotherapy | Usage | Cyclophosphamide | Multiple myeloma | Dosage and administration | Doxorubicin | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2018, Volume 182, Issue 2, pp. 231 - 244
Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma ( NDMM ) patients. This phase 1/2... 
newly diagnosed | multiple myeloma | oral | ixazomib | twice‐weekly | twice-weekly | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | PROTEASOME INHIBITOR IXAZOMIB | CYCLOPHOSPHAMIDE | AUTOLOGOUS TRANSPLANTATION | OPEN-LABEL | MAINTENANCE THERAPY | CARFILZOMIB | CONSOLIDATION THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Aged, 80 and over | Lenalidomide - pharmacokinetics | Adult | Female | Glycine - administration & dosage | Glycine - pharmacokinetics | Dexamethasone - administration & dosage | Drug Administration Schedule | Administration, Oral | Boron Compounds - pharmacokinetics | Treatment Outcome | Dexamethasone - pharmacokinetics | Disease-Free Survival | Lenalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lenalidomide - adverse effects | Boron Compounds - adverse effects | Aged | Complications and side effects | Medical research | Care and treatment | Hyperglycemia | Dexamethasone | Multiple myeloma | Medicine, Experimental | Steroids | Toxicity | Pharmacology | Pharmacokinetics | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
Ultrasound in Obstetrics & Gynecology, ISSN 0960-7692, 09/2016, Volume 48, Issue S1, pp. 328 - 328
Journal Article
Blood, ISSN 0006-4971, 11/2015, Volume 126, Issue 20, pp. 2284 - 2290
Journal Article